Allied Corp.

  • ISIN: US0191141078
  • Land: .

Nachricht vom 24.09.2019 | 12:03

Allied Corp., a Medical Cannabis Company, Approved to Uplist to OTCQB Venture Market

DGAP-News: Allied Corp. / Key word(s): Miscellaneous

24.09.2019 / 12:03
The issuer is solely responsible for the content of this announcement.


Kelowna, British Columbia--(Newsfile Corp. - September 24, 2019) - Allied Corp. (OTCQB: ALID) ("Allied"), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions, is pleased to announce its common stock is approved for trading on the OTCQB Venture Market.

The OTCQB is a venture market operated by OTC Markets Group and established for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. The OTCQB platform will allow Allied to provide investors increased transparency by providing the information needed to analyze, value and trade.

"Uplisting Allied Corp. to the OTCQB Venture Market is an exciting milestone for our company, highlighting our efforts to not only secure a foothold in the industry, but also to have a positive impact in the global cannabis industry" said CEO of Allied, Calum Hughes. "We are on track for growth and are focused on our strategic corporate plans as we continue to expand globally."

Additional information about Allied Corp. can be found at www.allied.health.

On behalf of the Board,

Calum Hughes
Chief Executive Officer

About Allied Corp.

Allied Corp. is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

Media Contact:
allied@5wpr.com
Investor Relations:
Anthony Zelen
ir@allied.health
+1-778-388-5258

Forward-Looking Statements:

This news release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or future performance. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as "anticipate", "become", "objective", "may", "will", "might", "should", "could", "can", "intend", "expect", "believe", "estimate", "predict", "potential", "plan", "is designed to", "project", "continue", or similar expressions suggest future outcomes or the negative thereof or similar variations. Such forward-looking statements include, but are not limited to, that the Company will experience growth and will be able to expand globally.. We are also subject to various additional risks as described in our SEC filings at www.SEC.gov.

Forward-looking statements are based on management's current expectations and may materially differ from actual results. Further, such forward-looking statements and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48074

Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/48074
News Source: Newsfile


24.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.